Biotech Calendar: Key FDA Action Dates
Drug/indication: Nebido for testosterone replacement
FDA decision date: Sept. 2
Nebido is a long-acting injectable testosterone that Endo picked up when it acquired Indevus Pharmaceuticals.
Drug/indication: Zevalin for non-Hodgkin's lymphoma
FDA decision date: Sept. 7
Spectrum has a new FDA approval decision date following a July 5 request from the agency for additional clinical data. Spectrum submitted that data on July 9. Spectrum is seeking an expansion to the label for Zevalin to include consolidation therapy for patients with NHL. Zevalin is an effective drug that has been a commercial disappointment, so the company hopes the expanded FDA label will boost sales.Auxilium Pharmaceuticals (AUXL)
Drug/indication: Xiaflex for Dupuytren's contracture
FDA decision date: Aug. 28
FDA advisory panel date: Sept. 16 Xiaflex is designed to dissolve collagen deposits that form cords around joints in the hands and cause the fingers to contract and become inflexible. Notice that the advisory panel's review of Xiaflex is scheduled for after the FDA approval decision date, which likely means a delay. Theravance (THRX)
Drug/indication: Telavancin for bacterial infections
FDA decision date: Sept. 16 The FDA review of telavancin for complicated skin and skin structure infections was delayed by the agency's request for additional information. Theravance is also seeking approval of telavancin for hospital-acquired pneumonia, with a second FDA approval decision date of Nov. 26. Eurand Pharmaceuticals (EURX)
Drug/indication: Zenpep for pancreatic insufficiency
FDA decision date: Sept. 24 Zenpep is a pancreatic enzyme replacement product for patients with pancreatic insufficiencies, a condition associated with cystic fibrosis, chronic pancreatitis and other diseases.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV